Ann: Opyl - Opin enters global strategic alliance, page-17

My take on it all is, forget the AI tag (AI ranges from being very basic to trying to simulate the human brain, with lots of companies spinning the AI card to pump the share price and try to give the impression they are far more cutting edge than they actually are), the access to trials provide hope to a lot of people who have been diagnosed with life changing diseases, cancer, parkinsons, MS, and the list goes on and on and on. To have a platform that can match eligible patient with trials on a base level (if done well) would be a phenomenal success for medicine, for patients and for shareholders.